Can a single dose of psilocybin treat depression?
Yes, at least for a while. In this clinical trial, one 25 mg dose of psilocybin eased major depression within 8 days, beating an active placebo by about 7 points on a standard depression scale. The benefit held for weeks, but by one year the two groups looked about the same.
Psilocybin is the active compound found in certain mushrooms. Researchers at the Karolinska Institutet in Sweden wanted to see whether a single dose could lift depression that had been hard to treat. They studied 35 adults with moderate-to-severe major depression. Each person also received talk therapy and support before, during, and after their dose. This kind of care matters, because psilocybin can bring up strong emotions that are easier to handle with a guide nearby.
To make the test fair, the study was double-blind. That means neither the patients nor the doctors knew who got the real drug. Half the group received a single 25 mg dose of psilocybin by mouth. The other half got niacin, a form of vitamin B3, as an active placebo. Niacin can cause a mild flush or tingling, so it helped hide which pill was which. This is a stronger test than a sugar pill, because it makes the comparison harder to guess.
What the data show
The early results were striking. By day 8, people who took psilocybin had a much bigger drop in their depression scores than the placebo group. The gap measured 7.27 points on the MADRS, a common scale doctors use to rate how severe depression is. A change of that size is meaningful, and it showed up in just over a week.
The edge did not vanish right away. On the clinician-rated scores, psilocybin stayed ahead through day 42, about six weeks after the dose. On the scores patients reported themselves, the benefit lasted even longer, out to day 102, or roughly three months. That is a long stretch of relief from a single treatment, which is part of why psilocybin has drawn so much interest as a depression treatment.
By one year, though, the picture changed. The difference between the two groups was no longer statistically significant. In plain terms, the psilocybin group and the placebo group ended up looking similar after twelve months. The fast start did not turn into a clear long-term win.
Dr. Kumar’s Take
What grabs my attention here is the speed. Standard antidepressants often take four to six weeks to work, and many people quit before they feel better. Seeing a real shift by day 8 from a single dose is remarkable, and the three-month tail of benefit is even more so. For someone stuck in deep depression, fast relief can be life-changing.
But I read the one-year result as a healthy dose of reality. A single dose is not a permanent cure. The benefit faded, which raises a fair question: do people need repeat sessions, ongoing therapy, or some mix to keep the gains? I also want to be careful, because this was a small study. Thirty-five people is enough to spot a strong early signal, but not enough to settle the long game. This is promising, not proven.
Study snapshot
The trial came from the Karolinska Institutet, a respected research center in Sweden. It enrolled 35 adults living with moderate-to-severe major depression. Researchers randomly split them into two groups. One group took a single 25 mg oral dose of psilocybin. The other took niacin as an active placebo. Both groups received the same psychotherapeutic support, so the only real difference was the pill itself. The double-blind design and the active placebo are real strengths, because they cut down the chance that hope or expectation alone explained the results.
Why the benefit may have faded
The study cannot tell us exactly why the advantage shrank over a year, but the pattern is worth thinking about. Depression is often a long-term condition that comes and goes. A single treatment, even a powerful one, may simply wear off as life stress returns. It is also possible the placebo group slowly improved on their own, with time and the talk therapy everyone received. That would narrow the gap without psilocybin itself getting worse. Either way, the result points to the same open question: how do you make early gains last?
Practical Takeaways
- Psilocybin is not an approved or legal depression treatment in most places, so do not try it on your own, as the dose and setting in this trial were carefully controlled by clinicians.
- If you are interested in this approach, ask your doctor about clinical trials, which are the only safe and legal way to access psilocybin therapy right now.
- Remember that the support therapy was part of the treatment, so any future use will likely pair the drug with structured counseling rather than the pill alone.
- If you are currently in treatment for depression, stay with your prescribed plan, since this single-dose effect faded by one year and is not a proven replacement for ongoing care.
Related Studies and Research
- Single-dose psilocybin vs placebo: the first double-blind depression trial
- Single-dose psilocybin shows rapid, sustained antidepressant effects
- Mindfulness-based therapy for depression in students: dose-response, inflammation, and BDNF
- SAMe as an add-on for major depression: a clinical trial
FAQs
Is psilocybin legal to use for depression?
In most countries, psilocybin is still a controlled substance and is not approved as a standard depression treatment. The doses in this study were given inside a research setting with medical staff present. A few regions have begun allowing supervised therapeutic use, but access is rare and tightly regulated. The safest and most legal path is to join an approved clinical trial, where doctors screen patients and watch over them closely.
What is the MADRS score, and why does a 7-point change matter?
MADRS stands for the Montgomery-Asberg Depression Rating Scale. Clinicians use it to rate the severity of depression symptoms like sadness, sleep problems, and loss of interest. Higher scores mean worse depression. A between-group difference of 7.27 points, like the one seen by day 8, is large enough to reflect a real, noticeable change in how someone feels, not just a number on a chart.
Why did the niacin placebo matter in this trial?
Niacin is a form of vitamin B3 that can cause a warm flush or tingling skin. Researchers used it as an active placebo so that people in the comparison group felt something happen too. This makes it harder for patients to guess whether they got the real drug. Because psilocybin’s effects are so strong, a plain sugar pill would be easy to spot. The active placebo makes the results more trustworthy.
Bottom Line
A single 25 mg dose of psilocybin, paired with therapy, produced a fast and meaningful drop in major depression symptoms within 8 days, and that edge over an active placebo held for weeks to a few months. By one year, the difference faded and the two groups looked similar. The trial captures both sides of the psilocybin story: real, rapid relief from a single dose, and the unanswered question of how to make that relief last.
